Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2015

Published: Jul, 2015 | Pages: 51 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2015', provides an overview of the Female Hypoactive Sexual Desire Disorder's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Female Hypoactive Sexual Desire Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Female Hypoactive Sexual Desire Disorder and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Female Hypoactive Sexual Desire Disorder
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Female Hypoactive Sexual Desire Disorder and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Female Hypoactive Sexual Desire Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Female Hypoactive Sexual Desire Disorder pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Female Hypoactive Sexual Desire Disorder
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Female Hypoactive Sexual Desire Disorder pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Female Hypoactive Sexual Desire Disorder Overview 6
Therapeutics Development 7
Pipeline Products for Female Hypoactive Sexual Desire Disorder - Overview 7
Pipeline Products for Female Hypoactive Sexual Desire Disorder - Comparative Analysis 8
Female Hypoactive Sexual Desire Disorder - Therapeutics under Development by Companies 9
Female Hypoactive Sexual Desire Disorder - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Female Hypoactive Sexual Desire Disorder - Products under Development by Companies 12
Female Hypoactive Sexual Desire Disorder - Companies Involved in Therapeutics Development 13
Apricus Biosciences, Inc. 13
Emotional Brain BV 14
Palatin Technologies, Inc. 15
Female Hypoactive Sexual Desire Disorder - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Combination Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
(bupropion hydrochloride + trazodone hydrochloride) - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
(sildenafil citrate + testosterone) - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
alprostadil - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
bremelanotide - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
flibanserin - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Female Hypoactive Sexual Desire Disorder - Recent Pipeline Updates 35
Female Hypoactive Sexual Desire Disorder - Dormant Projects 43
Female Hypoactive Sexual Desire Disorder - Dormant Projects 43
Female Hypoactive Sexual Desire Disorder - Product Development Milestones 44
Featured News & Press Releases 44
Jun 05, 2015: S1 Biopharma Supports FDA Advisory Committee's Recommendation to Approve the First-Ever Treatment for Hypoactive Sexual Desire Disorder 44
Jun 04, 2015: Palatin Supports FDA Advisory Committee's Recommendation to Approve the First-Ever Treatment for Hypoactive Sexual Desire Disorder 44
Jun 02, 2015: FDA Advisory Committee to Review Sprout Pharma's HSDD Drug 44
Mar 04, 2015: UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets 45
Feb 17, 2015: Sprout Pharmaceuticals Resubmits Flibanserin New Drug Application For The Treatment Of Hypoactive Sexual Desire Disorder In Premenopausal Women 45
Jan 07, 2015: Sprout Pharmaceuticals To Present At 33rd Annual J.P. Morgan Healthcare Conference 46
Nov 22, 2014: Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 46
Nov 22, 2014: Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released At Sexual Medicine Society of North America Meeting 47
Feb 11, 2014: Sprout Pharmaceuticals Receives Clear Guidance From FDA On Path Forward To Resubmit New Drug Application For Flibanserin, The First Potential Medical Treatment For Hypoactive Sexual Desire Disorder In Premenopausal Women 48
Dec 11, 2013: Sprout Pharmaceuticals Appeals FDA Decision On New Drug Application For Flibanserin To Treat Hypoactive Sexual Desire Disorder In Premenopausal Women 48
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 50
Disclaimer 51

List of Tables

Number of Products under Development for Female Hypoactive Sexual Desire Disorder, H2 2015 7
Number of Products under Development for Female Hypoactive Sexual Desire Disorder - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Late Stage Development, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Products under Development by Companies, H2 2015 12
Female Hypoactive Sexual Desire Disorder - Pipeline by Apricus Biosciences, Inc., H2 2015 13
Female Hypoactive Sexual Desire Disorder - Pipeline by Emotional Brain BV, H2 2015 14
Female Hypoactive Sexual Desire Disorder - Pipeline by Palatin Technologies, Inc., H2 2015 15
Assessment by Monotherapy Products, H2 2015 16
Assessment by Combination Products, H2 2015 17
Number of Products by Stage and Target, H2 2015 19
Number of Products by Stage and Mechanism of Action, H2 2015 21
Number of Products by Stage and Route of Administration, H2 2015 23
Number of Products by Stage and Molecule Type, H2 2015 25
Female Hypoactive Sexual Desire Disorder Therapeutics - Recent Pipeline Updates, H2 2015 35
Female Hypoactive Sexual Desire Disorder - Dormant Projects, H2 2015 43